Compare SPRO & RMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRO | RMBI |
|---|---|---|
| Founded | 2013 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.7M | 128.8M |
| IPO Year | 2017 | 2019 |
| Metric | SPRO | RMBI |
|---|---|---|
| Price | $2.28 | $14.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 281.7K | 23.2K |
| Earning Date | 11-13-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 4.24% |
| EPS Growth | N/A | ★ 21.88 |
| EPS | N/A | ★ 1.06 |
| Revenue | $40,549,000.00 | ★ $44,970,551.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.37 |
| Revenue Growth | N/A | ★ 6.42 |
| 52 Week Low | $0.51 | $11.37 |
| 52 Week High | $3.22 | $15.24 |
| Indicator | SPRO | RMBI |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 54.86 |
| Support Level | $2.26 | $13.88 |
| Resistance Level | $2.37 | $14.28 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 12.12 | 53.27 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.